Cancer-related fatigue and associated disability in post-treatment cancer survivors
the ONA take:
Cancer-related fatigue (CRF) is the most common symptom for patients with cancer. However, data on its prevalence in the posttreatment period is limited.
Using a self-administered mail-based questionnaire, these researchers sought to measure occurrence of CRF in three cohorts (16 to 18 months posttreatment, 2 to 3 years posttreatment, and 5 to 6 years posttreatment) of disease-free survivors of breast, prostate, or colorectal cancer.
The study generated a 63% response rate (2,294 questionnaire packages were returned). Twenty-nine percent of respondents reported significant fatigue, although fatigue levels did not differ between time cohorts.
Reports of fatigue were significantly higher in survivors of breast or colorectal cancer compared with survivors of prostate cancer.
The researchers conclude that approximately one-third of cancer survivors experience fatigue for up to 6 years after treatment. Clinicians should be aware that fatigue can be a chronic condition, and should routinely assess for it.
Cancer-related fatigue is the most common symptom for patients with cancer.
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|